COMPANY

Mabloc

HQ: Washington, DC source · mabloc.com ↗ · Mid-Atlantic

At Mabloc, we’ve developed the BRAID™ platform—Broadly Reactive Antibody Isolation & Development—to advance therapeutic development. From company website Source · Oct 12, 2026

Keywords: Antibody

Location: Washington, DC · source · Oct 14, 2026

Profile checked Oct 10, 2026

4NIH grants

NIH awards 4

Annual award amounts. Total $3.3M.

Aug 10, 2023 NIH award 5R42AI155275-04 FY2023: $978,679 awarded for that fiscal year; activity R42 (STTR); PI WATKINS, DAVID I; recipient as written: MABLOC, LLC, WASHINGTON, DC. Learning from the Ebola success: Can a mAb also sa source ↗
Jul 21, 2022 NIH award 5R42AI155275-03 FY2022: $988,498 awarded for that fiscal year; activity R42 (STTR); PI WATKINS, DAVID I; recipient as written: MABLOC, LLC, WASHINGTON, DC. Learning from the Ebola success: Can a mAb also sa source ↗
Aug 6, 2021 NIH award 4R42AI155275-02 FY2021: $999,410 awarded for that fiscal year; activity R42 (STTR); PI WATKINS, DAVID I; recipient as written: MABLOC, LLC, WASHINGTON, DC. Learning from the Ebola success: Can a mAb also sa source ↗
Jul 2, 2020 NIH award 1R42AI155275-01 FY2020: $299,598 awarded for that fiscal year; activity R42 (STTR); PI SACHA, JONAH B.; recipient as written: MABLOC, LLC, WASHINGTON, DC. Learning from the Ebola success: Can a mAb also sav source ↗